6OM Stock Overview
Operates as a healthcare solutions company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Owens & Minor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.50 |
| 52 Week High | US$25.80 |
| 52 Week Low | US$10.60 |
| Beta | 0.41 |
| 11 Month Change | -10.16% |
| 3 Month Change | -19.58% |
| 1 Year Change | -32.75% |
| 33 Year Change | -69.59% |
| 5 Year Change | 103.76% |
| Change since IPO | -37.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6OM | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -6.5% | 1.0% | -0.5% |
| 1Y | -32.7% | 19.2% | 8.3% |
Return vs Industry: 6OM underperformed the German Healthcare industry which returned 19.2% over the past year.
Return vs Market: 6OM underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| 6OM volatility | |
|---|---|
| 6OM Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6OM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6OM's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1882 | 22,200 | Ed Pesicka | www.owens-minor.com |
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.
Owens & Minor, Inc. Fundamentals Summary
| 6OM fundamental statistics | |
|---|---|
| Market cap | €897.99m |
| Earnings (TTM) | -€46.34m |
| Revenue (TTM) | €10.13b |
0.1x
P/S Ratio-19.4x
P/E RatioIs 6OM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6OM income statement (TTM) | |
|---|---|
| Revenue | US$10.66b |
| Cost of Revenue | US$8.36b |
| Gross Profit | US$2.30b |
| Other Expenses | US$2.35b |
| Earnings | -US$48.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 21.59% |
| Net Profit Margin | -0.46% |
| Debt/Equity Ratio | 213.8% |
How did 6OM perform over the long term?
See historical performance and comparison